Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 23;14:5309–5314. doi: 10.2147/OTT.S333242

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A–C) Right lung lesions showed by CT scan (arrows). (A) Right upper lobe mass (arrow) measures approximately 4.0 cm shows in the first chest CT scan. (B) The lung lesions shrunk after PD-1/PD-L1 inhibitors treatment. (C) The lung lesions remained stable after discontinuation of pembrolizumab for eight month. (D–F) Liver metastatic lesions shown by CT scan. (D) Liver metastatic lesions (arrow) measures approximately 1.7 cm showsin the first abdominal CT scan. (E) Liver metastatic lesions measures approximately 1.1 cm after PD-1/PD-L1 inhibitors treatment. (F) Liver metastatic lesions disappeared after discontinuation of pembrolizumab for eight month.